ERBB2 and invasive breast carcinoma: In particular, the TNBC phenotype (ER/PgR/HER2–negative), which accounts for 10-24% of invasive breast cancers, is characterized by earlier onset, poor prognosis, and limited therapeutic options [3], therefore, it may represent a priority epidemiological research target [21].